AM281, Cannabinoid Antagonist/Inverse agonist, Ameliorates Scopolamine-Induced Cognitive Deficit


Department of Pharmacology, Isfahan Pharmaceutical Sciences Research Centre, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran


Cannabinoids have been implicated in memory deficit. We examined the effect of AM281, cannabinoid antagonist/inverse agonist in prevention of scopolamine-induced cognitive deficit.
Materials and Methods 
Object recognition task was used to evaluate memory in mice. Exploration time in the first and the second trial was recorded. The differences in exploration between a previously seen object and a novel object in second trial were taken as an index of memory. Scopolamine and AM281 were administrated at the same time, 40 min before second trial in the treatment group.
Object discrimination was impaired after scopolamine (2 mg/kg; IP) administration. AM281 (2.5, 5 mg/kg; IP) significantly restored object recognition ability in mice treated with scopolamine by 75%.
This study extends earlier findings, suggesting the interaction of cannabinoid and cholinergic system in memory. Additionally cannabinoid antagonists seem to show variable pharmacological properties.


1.Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217:408–414.
2.Roloff E, Harbaran D, Micheau J,Platt B, Riedel G. Dissociation of cholinergic function in spatial and procedural learning in rats. Neurosci  2007; 146:875-889.
3.Carlini EA, Hamaoui A, Bieniek D, Korte F. Effects of (−) delta-9-trans-tetrahydrocannabinol and a synthetic derivative on maze performance of rats. Pharmacol 1970; 4:359–368.
4.Terranova  JP,  Storme JJ, Lafon N, Perio A, Rinaldi-Carmona M, Le Fu G, et al. Improvement of memory in rodents by the selective CB1 cannabinoid antagonist, SR141716. Psychopharmacology 2007; 126:165–172.
5.Thiel CM. Cholinergic modulation of learning and memory in the human brain as detected with functional neuroimaging. Neurobiol Learn Mem 2003; 80:234–244.
6. Mazzola M, Micale V, Drago F. Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. Eur J Pharmacol  2003; 477:219–225.
7.Naoto R, Takahashi RN, Pamplona FL, Fernandes MS. The cannabinoid antagonist SR141716A facilitates memory acquisition and consolidation in the mouse elevated T-maze. Neuroscie Lett  2005; 380:270-275.
8. Bruin NM, Prickaerts J, Lange JH, Akkerman S, Andriambeloson E, Haan M, et al. SLV330, a cannabinoid CB1 receptor antagonist, ameliorates deficits in the T-maze, object recognition and social recognition tasks in rodents. Neurobiol Learn Mem 2010; 934:522-531.
9. Cosenza M, Gifford AN, Gatley SJ,  Pyatt B, Liu Q,  Makriyannis  A, et al.  Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281. Synapse  2000; 38:477-482.
10.Bertaina-Anglade V, Enjuanes E, Morillon D, Drieu la Rochelle C. The object recognition task in rats and mice: simple and rapid modelin safety pharmacology to detect amnesic properties of a new chemical entity. J Pharmacol Toxicol Methods 2006; 54:99-105.
11.Van Meer P, Raber J.  Mouse behavioral analysis in systems biology. Biochem J 2005; 389:593-610.
12.Okuda S, Roozendaal B, McGaugh JL. Glucocorticoid effects on object recognition memory require training-associated emotional arousal. Proc Natl Acad Sci 2004; 101:853-857.
13.Reibaud M, Obinu MC, Ledent C, Parmentier M, Bohme GA, Imperato A. Enhancement of memory in cannabinoid CB1 receptor knockout mice. Eur J Pharmacol 1999; 379:1-2.
14. Dillona GM, Lubbersb LS, Fergusona MT, Laoc JZ, Huang RC, Xiao JC, et al. MK-7128, a novel CB1 receptor inverse agonist, improves scopolamine-induced learning and memory deficits in mice. Behav Pharmacol 2011; 22:92-100.
15.Gifford AN, Tang Y, Gatley SJ, Volkow ND, Lan R, Makriyannis A. Effect of the cannabinoid  receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices. Neurosci Lett 1997; 238:84-86.